Clinical Trials
6 trialsNCT02452554 2022-01-13
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Children's Oncology Group
Phase 2 Completed
NCT02420873 2018-08-28
An Open-label Phase II Study of Lorvotuzumab Mertansine
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00346385 2015-03-26
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
ImmunoGen, Inc.
Phase 1 Completed
NCT00991562 2014-11-21
IMGN901 in Combination With Lenalidomide and Dexamethasone
ImmunoGen, Inc.
Phase 1 Completed
NCT00346255 2013-04-23
IMGN901
ImmunoGen, Inc.
Phase 1 Completed
NCT00065429 2012-07-18
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
ImmunoGen, Inc.
Phase 1/2 Completed